Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 25Pancreatic Neoplasms 19Neoplasm Metastasis 17Neuroblastoma 8Lung Neoplasms 6Rhabdomyosarcoma 5Rectal Neoplasms 5Neoplasms 5Esophageal Squamous Cell Carcinoma 5Colonic Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma, Ewing 4Sarcoma 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Wilms Tumor 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Kidney Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

Bevacizumab 2repotrectinib 1Oviposition 1Leucovorin 1Irinotecan 1Fluorouracil 1Drug Therapy 1Drainage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Neoplasms × Irinotecan × 90 days × Clear all
NCT03303495 2026-06-05

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Sun Yat-sen University

Phase 3 Recruiting
280 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡